Blueprint Medicines Corp is a biopharmaceutical company that focuses on delivering transformative therapies for patients. The company is driven by a clear set of values and corporate philosophy. Blueprint Medicines Corp stands for innovation, collaboration, and a strong commitment to patients and their families. With a team of dedicated professionals, the company strives to make a meaningful impact on patients' lives by advancing precision medicine. By leveraging their expertise in genomics, Blueprint Medicines Corp aims to develop highly selective medicines to target genetic drivers of disease. Through their relentless pursuit of excellence, the company seeks to redefine the treatment landscape and provide hope for patients in need.

Blueprint Medicines Corp is primarily present in the United States.

Blueprint Medicines Corp has achieved several significant milestones. The company received accelerated approval from the U.S. Food and Drug Administration (FDA) in 2020 for its drug, Ayvakit, to treat certain types of advanced gastrointestinal stromal tumors (GIST). In the same year, Blueprint Medicines Corp also obtained FDA approval for its drug, Gavreto, to treat metastatic rearranged during transfection (RET) fusion-positive non-small cell lung cancer. These approvals signify the company's progress in developing targeted therapies for oncology patients. Additionally, Blueprint Medicines Corp has collaborated with various pharmaceutical companies to expand its research and development efforts, further establishing itself as a leader in precision medicine.

Blueprint Medicines Corp is a leading biopharmaceutical company that focuses on developing highly targeted therapies for genomically defined diseases. Founded in 2008, Blueprint Medicines Corp has a rich history in precision medicine, utilizing a deep understanding of genomics to identify and address the underlying genetic drivers of various diseases. The company has built a strong portfolio of investigational drugs that target specific genetic abnormalities, with a particular emphasis on cancers, rare diseases, and immunological disorders. Through its innovative approach, Blueprint Medicines Corp aims to bring transformative treatments to patients in need, driving advancements in personalized medicine and improving clinical outcomes.

The main competitors of Blueprint Medicines Corp in the market include companies such as Amgen, Novartis, and Pfizer.

Blueprint Medicines Corp is primarily active in the biotechnology and pharmaceutical industries.

Blueprint Medicines Corp's business model revolves around developing targeted therapies for genetically defined diseases. The company focuses on precision medicines that target the root cause of diseases at a molecular level. Blueprint Medicines combines deep understanding of disease biology with advanced scientific techniques to identify and develop therapeutics that address unmet medical needs. By leveraging their proprietary research platform and strong scientific expertise, the company aims to discover and advance multiple drug candidates, ultimately delivering transformative treatments to patients. Blueprint Medicines Corp's business model prioritizes innovation, scientific rigor, and strategic partnerships to improve patient outcomes in areas such as oncology and rare genetic disorders.

Az Blueprint Medicines P/E mutatója -62,73.

Az Blueprint Medicines KUV 10,31.

Az AlleAktien Minőségi Score Blueprint Medicines esetében 3/10.

A várt Blueprint Medicines forgalma 504,99 Mió. USD.

A(z) várt Blueprint Medicines nyereség -83,02 Mió. USD.

Blueprint Medicines Corp is a biopharmaceutical company specializing in the development of precision medicine for cancer and rare diseases. The company uses a proprietary platform for the discovery and development of kinase inhibitors to identify potential clinical candidates for personalized treatment. The business model of Blueprint Medicines is focused on three main areas: research and development, product commercialization, and partnerships. Research and development is at the core of the business model as the company focuses on developing drugs for indications where existing treatment options are inadequate or nonexistent. The company has a range of products in various stages of clinical development, including Avapritinib, Pralsetinib, AYVAKIT, and GZ/SAR439859. Avapritinib is a kinase inhibitor being developed for the treatment of gastrointestinal stromal tumors and systemic mastocytosis. Pralsetinib is an oral selective RET inhibitor being developed for the treatment of patients with RET-altered thyroid cancer and non-small cell lung cancer. AYVAKIT is a selective inhibitor of KIT and PDGFRA being developed for the treatment of patients with advanced basal cell carcinoma with KIT and PDGFRA mutations. GZ/SAR439859 is a selective BRAF inhibitor being developed for the treatment of patients with advanced melanoma and other solid tumors. Blueprint Medicines also operates a product commercialization division focused on the marketing and sale of already approved products and products in advanced stages of development. The company has an internal sales team responsible for marketing its products in the United States and also works with partners to sell its products internationally. Partnerships also play a key role in Blueprint Medicines' business model. The company has formed strategic partnerships with leading pharmaceutical and biotechnology companies such as Roche, CStone Pharmaceuticals, and Alexandria Real Estate Equities. These partnerships support the company's commitment to the development of precision medicine and provide access to resources and technologies to further expand its product portfolio. Overall, Blueprint Medicines' business model is focused on the development and commercialization of drugs for the treatment of cancer and rare diseases. The company pursues a comprehensive research and development strategy to identify potential clinical candidates and has a product pipeline focused on various indications. It also operates a product commercialization division and collaborates with leading pharmaceutical and biotechnology companies to build partnerships and sell products internationally.

A(z) Blueprint Medicines évente alkalommal oszt ki 0 USD összegű osztalékot.

A Blueprint Medicines esetében jelenleg nem lehet kiszámítani a osztalékot, vagy a vállalat nem fizet osztalékot.

A(z) Blueprint Medicines ISIN kódja: US09627Y1091.

A Blueprint Medicines WKN-je A14SDD.

Az Blueprint Medicines tőzsdei rövidítése BPMC.

Az elmúlt 12 hónapban a(z) Blueprint Medicines osztalékot fizetett összegben. Ez körülbelül osztalékhozamnak felel meg. A következő 12 hóban a(z) Blueprint Medicines várhatóan 0 USD összegű osztalékot fog fizetni.

A(z) Blueprint Medicines jelenlegi osztalékhozama .

A(z) Blueprint Medicines negyedévente fizet osztalékot. Az osztalékokat a következő hónapokban osztják ki: .

A Blueprint Medicines az elmúlt 0 évben minden évben fizetett osztalékot.

A következő 12 hónapban 0 USD összegű osztalékra számítanak. Ez 0 % osztalékhozamnak felel meg.

A(z) Blueprint Medicines a(z) 'Egészség' szektorhoz van besorolva.

Az utolsó, Blueprint Medicines által 2024. 10. 22.-án/én fizetett 0 USD összegű osztalék megszerzéséhez a részvénynek az ex-nap előtti 2024. 10. 22.-nál kellett lennie a portfóliódban.

Az utolsó osztalék kifizetése 2024. 10. 22. időpontban történt.

2023 évben a Blueprint Medicines 0 USD összegű osztalékot fizetett ki.

Az Blueprint Medicines osztalékait USD fizeti ki.